|
Market Closed -
Nasdaq
21:00:00 04/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 30.94 USD | +2.69% |
|
+7.24% | +17.51% |
| 10-27 | Zymeworks Inc. - Special Call | |
| 10-24 | Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026 | CI |
| Market Cap | 2.14B 1.9B 1.75B 1.59B 2.99B 202B 3.05B 20.78B 8.35B 107B 8.02B 7.85B 339B | P/E 2026 * |
28.2x | P/E 2027 * | 29.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1.89B 1.68B 1.54B 1.4B 2.64B 179B 2.7B 18.39B 7.39B 94.64B 7.1B 6.95B 300B | EV / Sales 2026 * |
6.38x | EV / Sales 2027 * | 4.87x |
| Free-Float |
92.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ZYME | Delayed | |
CBOE
| ZYME | Real-time | |
|
Boerse Muenchen
| ZA8 | Real-time | |
|
Tradegate
| ZA8 | Real-time | |
|
Deutsche Boerse AG
| ZA8 | Delayed | |
|
Börse Stuttgart
| ZA8 | Delayed |
Last Transcript: Zymeworks Inc.
| 1 day | +2.69% | ||
| 1 week | +7.24% | ||
| Current month | +8.14% | ||
| 1 month | +23.02% | ||
| 3 months | +41.86% | ||
| 6 months | +16.27% | ||
| Current year | +17.51% |
| 1 week | 28.26 |  | 31.49 |
| 1 month | 24.6 | | 31.49 |
| Current year | 21.52 | | 31.49 |
| 1 year | 16 | | 31.49 |
| 3 years | 6.83 | | 31.49 |
| 5 years | 4.11 | | 31.49 |
| 10 years | 4.11 | | 59.03 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ken Galbraith
CEO | Chief Executive Officer | 64 | 04/01/2022 |
Kristin Stafford
DFI | Director of Finance/CFO | 44 | 31/03/2026 |
Adam Schayowitz
CTO | Chief Tech/Sci/R&D Officer | 46 | 08/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Ken Galbraith
CHM | Chairman | 64 | 04/01/2022 |
Susan Mahony
BRD | Director/Board Member | 62 | 31/05/2019 |
Kelvin Neu
BRD | Director/Board Member | 52 | 29/02/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 09/10/26 | Exercice | Chief Technology Officer | 87,906 | 0.1239% | ||
| 06/07/26 | Free | Chief Operating Officer | 939 | 0.0013% | ||
| 13/05/26 | Free | EVP, General Counsel | 297,000 | 0.4027% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.69% | +7.24% | +63.79% | +316.42% | 2.14B | |
| +10.00% | +5.18% | +54.35% | +71.20% | 60.57B | |
| +1.44% | +4.06% | +22.70% | +101.03% | 55.51B | |
| +3.32% | +4.11% | +14.82% | +75.04% | 55.22B | |
| +0.46% | -2.86% | +23.34% | +33.77% | 43.27B | |
| +6.42% | +3.20% | +21.14% | +105.56% | 40.36B | |
| +2.82% | +7.24% | +236.59% | +801.17% | 41.63B | |
| -3.79% | +19.39% | +91.90% | +77.13% | 33.29B | |
| +5.32% | +6.04% | +20.27% | +52.98% | 32.27B | |
| +5.32% | +15.84% | -40.93% | +342.66% | 22.91B | |
| Average | +3.40% | +4.96% | +50.80% | +197.70% | 38.72B | |
| Weighted average by Cap. | +3.72% | +4.06% | +51.64% | +170.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 296M 264M 242M 220M 414M 28.05B 423M 2.88B 1.16B 14.83B 1.11B 1.09B 46.95B | 377M 336M 308M 280M 527M 35.67B 538M 3.66B 1.47B 18.86B 1.41B 1.38B 59.71B |
| Net income | 65.31M 58.14M 53.33M 48.47M 91.23M 6.18B 93.26M 635M 255M 3.27B 245M 240M 10.34B | 121M 107M 98.58M 89.59M 169M 11.42B 172M 1.17B 472M 6.04B 453M 443M 19.12B |
| Net Debt | -246M -219M -201M -183M -344M -23.3B -352M -2.39B -962M -12.32B -924M -904M -39B | -301M -268M -246M -223M -420M -28.47B -430M -2.92B -1.18B -15.05B -1.13B -1.1B -47.65B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/11/26 | US$30.94 | +2.69% | 1,044,852 |
| 03/11/26 | US$30.13 | +3.93% | 2,519,662 |
| 02/11/26 | US$28.99 | +1.33% | 1,175,583 |
| 30/10/26 | US$28.61 | -0.35% | 2,880,103 |
| 29/10/26 | US$28.71 | -0.66% | 806,233 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZYME Stock
Select your edition
All financial news and data tailored to specific country editions
